Annals of Hematology

, Volume 86, Issue 10, pp 711–717

Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab

  • Christof Schweizer
  • Frederic J. Reu
  • Anthony D. Ho
  • Manfred Hensel
Original Article


Idiopathic thrombocytopenic purpura (ITP), also known as immune thrombocytopenic purpura, is thought to be caused primarily by the production of autoantibodies directed against platelet surface glycoproteins. Treatment of an acute ITP episode can be difficult, and relapses are common. Recent studies have shown that the anti-CD20 antibody rituximab is effective in the treatment of relapsed and refractory patients. We report the results of a retrospective analysis of rituximab treatment in 14 patients with immune thrombocytopenic purpura. Nine of these patients had a refractory disease, and five patients had a relapse of the thrombocytopenia. The median time since last treatment was 10 days (range 1–470 days). All patients were previously treated with one to seven different regimens, and four had undergone splenectomy. Rituximab was administered at the standard dose of 375 mg/m2 once per week with a median of 4 infusions (range 2–4). The overall response rate was 64%; 7 of 14 patients (50%) achieved a complete remission (platelet levels > 100 × 109/l), 2 of 14 patients (14%) had a partial remission (platelets > 50 × 109/l), and 5 patients did not respond. The median time to response was 2 weeks (range 1–4) after the first infusion. Responding patients stayed in remission for a median period of 8 weeks (range 10 days–36 months). Three patients (21%) remained in remission after 26 to 156 weeks of follow-up. All of the four splenectomized patients achieved a complete remission after rituximab therapy, and two of them are still in remission after 26 and 156 weeks observation. Our data confirm that rituximab is well tolerated and effective in refractory and relapsed immune thrombocytopenias; however, response duration was short, and only about one fifth of our patients enjoyed a long-lasting remission.


ITP Idiopathic thrombocytopenic purpura Rituximab Anti-CD 20 Splenectomy 


  1. 1.
    Ahmad HN, Ball C, Height SE, Rees DC (2004) Rituximab in chronic, recurrent HIV-associated immune thrombocytopenic purpura. Br J Haematol 127:607–608PubMedCrossRefGoogle Scholar
  2. 2.
    Ahrens N, Kingreen D, Seltsam A, Salama A (2001) Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Haematol 114:244–245PubMedCrossRefGoogle Scholar
  3. 3.
    Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146:25–33PubMedGoogle Scholar
  4. 4.
    Bengtson KL, Skinner MA, Ware RE (2003) Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. J Pediatr 143:670–673PubMedCrossRefGoogle Scholar
  5. 5.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC (2005) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 78:275–280PubMedCrossRefGoogle Scholar
  6. 6.
    Bussel JB (2000) Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients. Semin Oncol 27:91–98PubMedGoogle Scholar
  7. 7.
    Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL (2006) AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355:1672–1681PubMedCrossRefGoogle Scholar
  8. 8.
    Carbone J, Escudero A, Mayayo M, Ballesteros M, Perez-Corral A, Sanchez-Ramon S, Sarmiento E, Micheloud D, Fernandez-Cruz E (2005) Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency. Ann NY Acad Sci 1051:666–671PubMedCrossRefGoogle Scholar
  9. 9.
    Choueiri T, Lichtin AE (2002) Hereditary hemorrhagic telangiectasia, idiopathic thrombocytopenic purpura, and chronic lymphocytic leukemia treated with rituximab. Am J Med 113:700–701PubMedCrossRefGoogle Scholar
  10. 10.
    Cines DB, Blanchette VS (2002) Immune thrombocytopenic purpura. N Engl J Med 346:995–1008PubMedCrossRefGoogle Scholar
  11. 11.
    Cines DB, McMillan R (2005) Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 56:425–442PubMedCrossRefGoogle Scholar
  12. 12.
    Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125:232–239PubMedCrossRefGoogle Scholar
  13. 13.
    Cooper N, Stasi R, Michel M, Bussel JB (2003) Retreatment of 11 patients with immune thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab [abstract]. Blood 102(Suppl):87bGoogle Scholar
  14. 14.
    Fianchi L, Rossi E, Murri R, de Stefano V, Pagano L, Leone G (2007) Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Ann Hematol 86:225–226PubMedCrossRefGoogle Scholar
  15. 15.
    George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3–40PubMedGoogle Scholar
  16. 16.
    Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, Aul C (2002) Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 69:95–100PubMedCrossRefGoogle Scholar
  17. 17.
    Grossi A, Santini V, Longo G, Balestri F, Ferrini P (2000) Treatment with anti CD 20 antibodies of patients with autoimmune thrombocytopenia with or without haemolytic anemia: worsening in hemoglobin level [abstract]. Blood 96(Suppl):253aGoogle Scholar
  18. 18.
    Hegde UP, Wilson WH, White T, Cheson BD (2002) Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 100:2260–2262PubMedGoogle Scholar
  19. 19.
    Hensel M, Ho AD (2003) Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab. Am J Hematol 73:37–40PubMedCrossRefGoogle Scholar
  20. 20.
    Imbach P (2003) Refractory idiopathic immune thrombocytopenic purpura in children: current and future treatment options. Paediatr Drugs 5:795–801PubMedCrossRefGoogle Scholar
  21. 21.
    Introna M, Golay J, Barbui T (2003) Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura? Haematologica 88:482–484PubMedGoogle Scholar
  22. 22.
    Jacoub J, Mchlayeh W, Tabbara I, Dave HP, Siegel R, Schechter GP (2004) The use of anti-CD20 chimeric monoclonal antibody, rituximab in adult patients with treatment refractory immune thrombocytopenia [abstract]. Blood 104:74bGoogle Scholar
  23. 23.
    Koene HR (2006) Critical issues of current and future developments in the treatment of immune thrombocytopenic purpura. Pediatr Blood Cancer 47:703–705PubMedCrossRefGoogle Scholar
  24. 24.
    Kojouri K, Vesely SK, Terrell DR, George JN (2004) Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104:2623–2634PubMedCrossRefGoogle Scholar
  25. 25.
    Lieb JV, Rossetti JM, Shadduck RK, Gryn JE, Kaplan RB, Zeigler ZR, Lister J (2003) Rituximab therapy for relapsed or refractory autoimmune thrombocytopenia [abstract]. Blood 102(Suppl):83bGoogle Scholar
  26. 26.
    Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M (2004) Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol 77:303–310PubMedCrossRefGoogle Scholar
  27. 27.
    McMillan R, Nugent D (2005) The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol 81:94–99PubMedCrossRefGoogle Scholar
  28. 28.
    Narang M, Penner JA, Williams D (2003) Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). Am J Hematol 74:263–267PubMedCrossRefGoogle Scholar
  29. 29.
    Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB (2005) Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 90:1273–1274PubMedGoogle Scholar
  30. 30.
    Papadakis KA, Rosenbloom B, Targan SR (2003) Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn’s disease. Gastroenterology 124:583PubMedCrossRefGoogle Scholar
  31. 31.
    Parodi E, Nobili B, Perrotta S, Rosaria Matarese SM, Russo G, Licciardello M, Zecca M, Locatelli F, Cesaro S, Bisogno G, Giordano P, De Mattia D, Ramenghia U (2006) Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol 84:48–53PubMedCrossRefGoogle Scholar
  32. 32.
    Penalver FJ, Jimenez-Yuste V, Almagro M, Alvarez-Larran A, Rodriguez L, Casado M, Gallur L, Giraldo P, Hernandez R, Menor D, Rodriguez MJ, Caballero D, Gonzalez R, Mayans J, Millan I, Cabrera JR (2006) Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 85:400–406PubMedCrossRefGoogle Scholar
  33. 33.
    Perrotta A, Abuel C (1998) Response of chronic relapsing ITP of 10 years duration to rituximab [abstract]. Blood 92(Suppl):88bGoogle Scholar
  34. 34.
    Perrotta A, Sunneberg TA, Scott J, Ratanatharaphorn V, Hook C, Attas L (1999) Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura (ITP) [abstract]. Blood 94(Suppl):14aGoogle Scholar
  35. 35.
    Perrotta AL (2006) Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review. Clin Appl Thromb Hemost 12:97–100PubMedCrossRefGoogle Scholar
  36. 36.
    Price S, Cumpston A, Altaha R (2006) Use of rituximab in refractory autoimmune thrombocytopenia following an autologous stem cell transplant. Hematology 11:43–44PubMedCrossRefGoogle Scholar
  37. 37.
    Raj K, Narayanan S, Augustson B, Ho A, Mehta P, Duncan N, Tauro S, Mahendra P, Craddock C, Mufti G (2005) Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplant 35:299–301PubMedCrossRefGoogle Scholar
  38. 38.
    Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G, Silver SM, Ferrara JL, Uberti JP (2000) Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 133:275–279PubMedGoogle Scholar
  39. 39.
    Robak T (2004) Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 72:79–88PubMedCrossRefGoogle Scholar
  40. 40.
    Russo G, Licciardello M, La Spina M (2004) Rituximab in children with idiopathic thrombocytopenic purpura: does it really work? Eur J Pediatr 163:569PubMedCrossRefGoogle Scholar
  41. 41.
    Sandler SG, Tutuncuoglu SO (2004) Immune thrombocytopenic purpura—current management practices. Expert Opin Pharmacother 5:2515–2527PubMedCrossRefGoogle Scholar
  42. 42.
    Shvidel L, Klepfish A, Berrebi A (2001) Successful treatment with rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin’s lymphoma. Am J Hematol 67:213–214PubMedCrossRefGoogle Scholar
  43. 43.
    Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952–957PubMedCrossRefGoogle Scholar
  44. 44.
    Stasi R, Stipa E, Forte V, Meo P, Amadori S (2002) Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 99:3872–3873PubMedCrossRefGoogle Scholar
  45. 45.
    Stevens W, Koene H, Zwaginga JJ, Vreugdenhil G (2006) Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. Neth J Med 64:356–363PubMedGoogle Scholar
  46. 46.
    Tamminga RY, Bruin MC (2006) Rituximab treatment for symptomatic chronic ITP. Pediatr Blood Cancer 47:714–716PubMedCrossRefGoogle Scholar
  47. 47.
    Tomietto P, Gremese E, Tolusso B, Venturini P, De Vita S, Ferraccioli G (2004) B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. Thromb Haemost 92:1150–1153PubMedGoogle Scholar
  48. 48.
    Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN (2004) Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med 140:112–120PubMedGoogle Scholar
  49. 49.
    Zaja F, Vianelli N, Battista M, Sperotto A, Patriarca F, Tomadini V, Fili C, Tani M, Baccarani M, Fanin R (2006) Earlier administration of rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 34:571–572PubMedCrossRefGoogle Scholar
  50. 50.
    Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, Molinari AL, Baccarani M, Fanin R (2003) B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 88:538–546PubMedGoogle Scholar
  51. 51.
    Zaja F, Vianelli N, Sperotto A, Patriarca F, Tani M, Marin L, Tiribelli M, Candoni A, Baccarani M, Fanin R (2003) Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 44:1951–1955PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Christof Schweizer
    • 1
  • Frederic J. Reu
    • 1
  • Anthony D. Ho
    • 1
  • Manfred Hensel
    • 1
  1. 1.Department of Internal Medicine V, Haematology, Oncology and RheumatologyUniversity of HeidelbergHeidelbergGermany

Personalised recommendations